MSB 2.17% $1.13 mesoblast limited

Ann: Confirmatory Phase 3 Back Pain Trial Actively Enrols, page-34

  1. 77 Posts.
    lightbulb Created with Sketch. 25


    Wonderful news, Mesoblast team! This achievement exemplifies our mission. The Phase 3 trial of Rexlemestrocel-L for chronic low back pain is a significant milestone. I look forward to more clinical readouts in the future, as we continue to develop this potential life-saving treatment as an alternative to painkillers.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.